Abstract: Provided is a transdermal preparation, which is capable of long-term (1-day to 7-day) release of a basic drug from a preparation, continuously and at a consistent concentration; shows little reduction over time in the drug content, even if multiple drugs are contained in the preparation; and is produced by a simple process. The transdermal preparation comprises a substrate, and an adhesive layer containing a basic drug and a water-soluble polymer.

Abstract: The present invention relates to aryl glycolipid gels as control release devices and uses thereof in agriculture. In an exemplary embodiment, mannitol dioctanoate (M8) is used to prepare controlled release devices for pheromones.

Abstract: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and copper or zinc compounds which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with one or more copper or zinc compounds selected from Cu2O, Cu(OH)2, CuSO4, copper pyrithione, CuSCN, CuCO3, ZnO, ZnCl2, ZnSO4, zineb, and zinc pyrithione; in respective proportions to provide a synergistic effect against fouling organisms and the use of these compositions for protecting materials against fouling organisms. This invention thus relates to the field of protection of materials, such as underwater objects, protection of wood, wood products, biodegradable materials and coatings.

Abstract: The present invention relates to an injectable anticancer composition for local administration comprising hydroxychloroquine. The anticancer composition shows an IC50 value against sarcoma-180 cells, which is about 10 times lower than cisplatin, as determined by the MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. Also, the anticancer composition shows dose-dependent effects against solid cancer induced by sarcoma-80 cells in vivo. In addition, the anticancer composition has the effect of extending the life expectancy of patients having ascites cancer induced by sarcoma-80 cells.

Abstract: Novel trehalose click polymers have in vitro and in vivo application in the cellular delivery of biologically active molecules, including nucleic acids and polypeptides. The trehalose click polymers of the present invention provide increased stability in serum as compared with other non-viral vectors, and are particularly useful in protecting nucleic acids against degradation.

Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders.

Abstract: Provided is a transdermal preparation, which is capable of long-term (1-day to 7-day) release of a basic drug from a preparation, continuously and at a consistent concentration; shows little reduction over time in the drug content, even if multiple drugs are contained in the preparation; and is produced by a simple process. The transdermal preparation comprises a substrate, and an adhesive layer containing a basic drug and a water-soluble polymer.

Abstract: The present application discloses a system for trapping flying insects, a first chemical lure such as lactic acid, a salt of lactic acid, or combinations thereof, and a second chemical lure comprising a source of ammonia. The lures may be employed in particular geometric shapes contained in specifically designed housing to ensure an effective release rate over extended periods of time.

Abstract: A method by which high-purity CMP-N-acetylneuraminic acid (HPLC purity, 95% or higher), which has been difficult to obtain with any technique other than chromatography, can be easily obtained in satisfactory yield by a simple operation without the need of chromatography. The process, which is for producing high-purity CMP-N-acetylneuraminic acid (CMP-NeuAc), is characterized by conducting a suitable combination of the following steps (1) to (4). Step 1: a step in which divalent cations are added to a solution containing CMP-NeuAc to thereby precipitate the phosphoric acid, pyrophosphoric acid, and nucleotide which coexist; Step 2: a step in which a phosphatase is added to a solution containing CMP-NeuAc to thereby convert the coexistent nucleotide into nucleoside; Step 3: a step in which an organic solvent is added to precipitate the CMP-NeuAc; and Step 4: a step in which the CMP-NeuAc precipitated is recovered.

Abstract: It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X (FXa), and is useful as an agent for preventing and/or treating thrombosis, wherein the pharmaceutical composition exhibits favorable dissolution properties. The present invention relates to a solid pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, wherein the content of the compound represented by formula (I) is 0.5% by weight or more and less than 15% by weight with respect to the total weight of the pharmaceutical composition.

Abstract: A skin care composition is useful for augmenting cellular metabolism in skin cells and thereby enhancing the regulation of intracellular signaling. The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations thereof. The composition may also include antioxidants for free radical regulation and a pharmaceutically acceptable topical vehicle, such as an emollient base for skin health. A method for stimulating the mitochondrial activity of skin cells comprises administering to the skin of a person in need thereof a composition as described herein.

Abstract: The present invention provides conjugates, processes for their preparation, and the use of these conjugates for transporting low-molecular-weight compounds and macromolecules across biological membranes, in particular for transporting molecules into cells. The present invention also provides pharmaceutical compositions, diagnostic aids, and test kits in which these conjugates are present or used.

Abstract: The present invention provides a tool for reducing the time and labor required for obtaining a protein by recombinant expression of a gene in a host. A vector characterized by having two restriction recognition sequences different in nucleotide sequence both of which are recognized by a first restriction enzyme, one of the restriction recognition sequences comprising a part of a restriction recognition sequence recognized by a second restriction enzyme that is different from the first restriction enzyme, and the other one of the restriction recognition sequences not comprising the part of the restriction recognition sequence recognized by the second restriction enzyme. A method of producing a protein and/or a protein domain, using the above-described vector.

Abstract: The present invention provides a method for transferring a gene into cells, which is practically useful and can achieve high transfer efficiency, and also a composition for use in the method. By bringing a mixture of a composition comprising a diallylamine sulfur dioxide copolymer having a repeating unit represented by the formula (1) or a salt thereof and a gene into contact with a cell, a gene such as DNA and RNA can be transferred into a target cell safely and conveniently, and into a cell at a specific site with high gene transfer efficiency.

Abstract: The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.

Abstract: Methods for processing microparticles involve providing a composition comprising a plurality of solid microparticles and at least one non-volatile material, providing a non-solvent, and exposing the composition to the non-solvent to remove at least a portion of the non-volatile material from the composition while retaining at least the microparticles.

Abstract: Agrochemical compositions comprising at least one active compound from the class of the anthranilamides and at least one further active compound selected from the group consisting of insecticides, fungicides, and/or acaricides have excellent synergistic activity.

Abstract: The use of a compound of formula I, wherein Y is a single bond, C?O, C?S or S(O)m where m is 0, 1 or 2; R?, R2, R3, R4, R8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6; q is 0, 1, 2, 3, 4, 5 or 6; provided that when p is 2 then q is not 2; p+q is 1, 2, 3, 4, 5 or 6; or salts or N-oxides thereof or compositions containing them and their using in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.

Abstract: The present invention relates to the cosmetic use of a compound of formula (I) and also the cosmetically acceptable salts thereof, solvates thereof and isomers thereof, for non-therapeutic skincare.